TY - JOUR
T1 - New therapies for neurovascular bundles regeneration after radical prostatectomy
T2 - A narrative review on clinical studies
AU - Rivero Belenchón, Inés
AU - Gómez Rivas, Juan
AU - Medina López, Rafael Antonio
AU - Checcucci, Enrico
AU - Taratkin, Mark
AU - Puliatti, Stefano
AU - Kowalewski, Karl Friedrich
AU - Cacciamani, Giovanni
AU - Congregado Ruíz, Carmen Belén
AU - Castro, Cristina
AU - Enikeev, Dmitry
AU - Abad-Lopez, Pablo
AU - Panetsos, Fivos
AU - Moreno-Sierra, Jesús
N1 - Publisher Copyright:
Copyright © 2022 Rivero Belenchón, Gómez Rivas, Medina López, Checcucci, Taratkin, Puliatti, Kowalewski, Cacciamani, Congregado Ruíz, Castro, Enikeev, Abad-Lopez, Panetsos and Moreno-Sierra.
PY - 2022
Y1 - 2022
N2 - Prostate cancer is the most common cancer amongst men, and one of its treatments in the localized stage is radical prostatectomy (RP). This technique achieves a high success rate regarding oncological results, but one of its main drawbacks are sexual disorders, especially erectile dysfunction, ranging from 14-90% of the cases. Therefore, surgery advancements in the last decade have been focused on minimizing the impact on patient’s functioning. Now is time for a step forward in the recovery of functional outcomes after RP. Bioengineering solutions such as stem-cell therapy and tissue engineering hold great opportunities for the treatment of all tissues and organs dysfunctions, which may help in neuroprotection and neuro-regeneration. Specifically, the use of Dehydrated human amnion/chorion membrane (dHACM) allografts and chitosan membranes (ChiMe) aims at reconstructing damaged neurovascular plexuses of the urogenital system to support erectile function recovery. Some research is being done on this topic, and promising results are emerging.
AB - Prostate cancer is the most common cancer amongst men, and one of its treatments in the localized stage is radical prostatectomy (RP). This technique achieves a high success rate regarding oncological results, but one of its main drawbacks are sexual disorders, especially erectile dysfunction, ranging from 14-90% of the cases. Therefore, surgery advancements in the last decade have been focused on minimizing the impact on patient’s functioning. Now is time for a step forward in the recovery of functional outcomes after RP. Bioengineering solutions such as stem-cell therapy and tissue engineering hold great opportunities for the treatment of all tissues and organs dysfunctions, which may help in neuroprotection and neuro-regeneration. Specifically, the use of Dehydrated human amnion/chorion membrane (dHACM) allografts and chitosan membranes (ChiMe) aims at reconstructing damaged neurovascular plexuses of the urogenital system to support erectile function recovery. Some research is being done on this topic, and promising results are emerging.
KW - erectile dysfunction
KW - neurovascular regeneration
KW - radical prostatectomy
KW - sexual potency
KW - stem cell therapy
KW - tissue engineering
UR - http://www.scopus.com/inward/record.url?scp=85183388390&partnerID=8YFLogxK
U2 - 10.3389/fruro.2022.923064
DO - 10.3389/fruro.2022.923064
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.systematicreview???
AN - SCOPUS:85183388390
SN - 2673-9828
VL - 2
JO - Frontiers in Urology
JF - Frontiers in Urology
M1 - 923064
ER -
